October 15, 2013
Dr. James Brophy is a Professor in the Departments of Medicine, and Epidemiology and Biostatistics at McGill University. He is also a staff physician in the Division of Cardiology at McGill University Health Centre (MUHC) and Graduate Program Director of Epidemiology, Biostatistics & Occupational Health. Dr. Brophy has been the recipient of numerous awards including the FRSQ-MSS-MUHC Research Chair in Technology Assessment and Evidence-based Medicine.
Dr. Brophy holds a B.Eng. and PhD from McGill University, a M.Eng. and MD from McMaster University, and completed a cardiology residency at the Université de Montreal. His research interests centre on cardiovascular epidemiology, drug safety, cost effectiveness, meta-analysis, and Bayesian statistics and decision-making. He has published over 100 articles in the peer-reviewed literature with several of his most recent contributions focusing on the cardiovascular safety of selective cyclooxygenase 2 inhibitors.
Dr. Brophy is a member of a number of professional associations including: the American College of Cardiology (Governor 2004 to 2008; Board of Governors Steering Committee 2006 to 2007; and Committee for Heart Failure and Cardiac Transplantation 2006 to 2008); the Scientific Council of Epidemiology of the American Heart Association; the Canadian Cardiovascular Society; the Royal College of Physicians and Surgeons of Canada; and the Quebec College of Physicians and Surgeons. Dr. Brophy has the distinction of serving as member of the editorial boards of the Canadian Journal of Cardiology (2009-), International Journal of Technology Assessment in Healthcare (2009-), Clinical Epidemiology & Risk Management (2008-), and Open Medicine (2006-).